COVID-19 convalescent plasma utilization in the United States: data from the National Inpatient Sample.
Evan M BlochRuchika GoelXianming ZhuEshan U PatelShmuel ShohamDavid J SullivanKelly GeboArturo CasadevallAaron A R TobianPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
COVID-19 convalescent plasma (CCP) use between October-December 2020 was characterized using the National Inpatient Sample database. CCP was administered in 18.0% of COVID-19-associated hospitalizations, and was strongly associated with older age and increased disease severity. There were disparities in the receipt of CCP by race and ethnicity, geography, and insurance.